Moving ahead toward clinical trials in treating neurodegeneration


Safety Studies

FDA approval

Gskure is an IP based company that owns innovative
proprietary GSK-3 peptide inhibitors drug candidates.

The Science Behind GSK-3 Inhibition

The protein GSK-3 is a causative factor behind a broad spectrum of neurodegenerative disorders. Inhibition of GSK-3 should limit the progression of neurodegeneration and rescue pathological symptoms.

Novel Strategy

Our Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed – the substrate binding site. Our substrate competitive inhibitors (SCIs) show improved selectivity and low toxicity, this, as compared to the traditionally used ATP competitive inhibitors.

Reducing Disease Severity

Using innovative therapy to improve patients quality of life.
Our Researches on in vivo models show recovery and improvement in:

  • Cognitive Functions
  • Mood Behaviour
  • Motor Coordination

Leading GSK-3 Implications Globally

Gskure uses the novel SCI strategy for drug design that has a significant advantage for clinical practice.
Professor Hagit Eldar-Finkelman, from Tel Aviv University, conducted pioneering studies in developing GSK-3
inhibitors and the therapeutic use in treating human disease.

Join Our Effort

Gskure is an IP based company dedicated to implicate its therapeutic approach for treating brain desires. To enhance our mission we are in search for partners to join our efforts.

  • Philanthropy
  • Biotech Enterprises
  • Government

Contact Us